NASDAQ: NTLAIntellia Therapeutics Inc Stock
$9.14+0.12 (+1.33%)
Updated Dec 15, 2025
NTLA Price
$9.14
Fair Value Price
N/A
Market Cap
$1.06B
52 Week Low
$5.90
52 Week High
$28.24
P/E
-2.15x
P/B
1.41x
P/S
33.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.53M
Earnings
-$445.81M
Gross Margin
100%
Operating Margin
-774.94%
Profit Margin
-774.9%
Debt to Equity
0.24
Operating Cash Flow
-$411M
Beta
1.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NTLA Overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NTLA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NTLA
Ranked#264 of 487
Ranked#264 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.14 | A | |
| $310.67 | A | |
| $7.59 | A |
Be the first to know about important NTLA news, forecast changes, insider trades & much more!
NTLA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NTLA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NTLA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NTLA is good value based on its book value relative to its share price (1.41x), compared to the US Biotechnology industry average (5.3x)
P/B vs Industry Valuation
NTLA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NTLA due diligence checks available for Premium users.
Valuation
NTLA fair value
Fair Value of NTLA stock based on Discounted Cash Flow (DCF)
Price
$9.14
Fair Value
-$11.52
Undervalued by
179.37%
NTLA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NTLA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.15x
Industry
148.94x
Market
45.07x
NTLA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
5.3x
NTLA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NTLA's financial health
Profit margin
Revenue
$13.8M
Net Income
-$101.3M
Profit Margin
-735.2%
NTLA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NTLA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$925.3M
Liabilities
$176.9M
Debt to equity
0.24
NTLA's short-term assets ($581.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTLA's short-term assets ($581.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTLA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTLA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$76.9M
Investing
-$741.0k
Financing
$114.9M
NTLA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NTLA vs Biotech Stocks
Intellia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.